683 Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

683 Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-217,265	Closed	-$539K	–	141
2024 Q4	$539K	Buy	+217,265	New	+$541K	0.03%	149
2021 Q1	–	Sell	-46,168	Closed	-$299K	–	170
2020 Q4	$299K	Buy	+46,168	New	+$195K	0.01%	184

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

683 Capital Management's ACRS Position: Q1 2025 in Review

683 Capital Management sold out of Aclaris Therapeutics (ACRS) in Q1 2025, closing a stake of 217,265 shares — an estimated $539K sold.

683 Capital Management first reported a position in ACRS in Q4 2020 and held it in 2 quarters. The position peaked at $539K in Q4 2024. 109 funds tracked by Wall St. Rank hold ACRS as of Q1 2025.

683 Capital Management reported no remaining Aclaris Therapeutics position as of Q1 2025 after selling out during the quarter.
683 Capital Management sold 217,265 Aclaris Therapeutics shares in Q1 2025, an estimated $539K.
683 Capital Management first reported a position in Aclaris Therapeutics in Q4 2020 and held it in 2 quarters.
683 Capital Management's Aclaris Therapeutics position peaked at $539K in Q4 2024.
109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2025.

Based on 683 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.